The objective of this research was to evaluate comparative pharmacokinetics of doramectin in alpacas, after subcutaneous administration of 0.2 mg/kg dose. Six healthy adult alpacas, mean age of 5 years ± 1, (three female and three gelded males) of mean bodyweight of 62 kg ± 16 kg with an average body condition scored 2.8 ± 1 out of five, were used in this study. Serial blood samples were collected from the jugular vein before the administration until day 21 afterwards to establish the pharmacokinetics of doramectin after its subcutaneous administration at 0.2 mg/kg dose. The blood samples were analysed using high-performance liquid chromatography (HPLC), fluorescence detection method with precolumn derivatisation, validated for alpacas. The pharmacokinetic parameters were calculated using a noncompartmental model, and results showed Cmax (6.05 ± 5.34 ng/ml), Tmax (3.83 ± 2.48 days), AUC (62.12 ± 18.86 ng/ml × d), terminal half-life (6.2 ± 4.9 days) and MRT (11.56 ± 4.43 days). The results of this study showed that the Cmax and AUC were much lower than in cattle and sheep at the same dosage. Tmax remained similar to cattle and sheep. This study presents valuable information about pharmacokinetics of doramectin in alpacas, which can be utilised in its future efficacy studies.

中文翻译：

---

羊驼皮中皮下注射多拉菌素的药代动力学。

这项研究的目的是评估皮下注射0.2 mg / kg剂量的多拉菌素在羊驼中的比较药代动力学。在本研究中，使用了六只健康的成人羊驼，平均年龄为5岁±1（三名女性和三名胶凝的男性），平均体重为62 kg±16 kg，平均身体状况得分为2.8±1，五分之二。在给药之前直至其后的第21天从颈静脉收集系列血液样品，以建立多拉克丁在0.2mg / kg剂量的皮下给药后的药代动力学。使用高效液相色谱（HPLC），带有柱前衍生化的荧光检测方法对血样进行分析，并验证了羊驼毛。使用非房室模型计算药代动力学参数，结果显示Cmax（6.05±5）。34 ng / ml），Tmax（3.83±2.48天），AUC（62.12±18.86 ng / ml×d），终末半衰期（6.2±4.9天）和MRT（11.56±4.43天）。这项研究的结果表明，在相同剂量下，Cmax和AUC远低于牛和羊。Tmax仍然与牛和绵羊相似。这项研究提供了关于多拉菌素在羊驼中的药代动力学的有价值的信息，可用于其未来的功效研究。